Atto Bioscience deal
This article was originally published in The Gray Sheet
Executive Summary
BD acquires optical instrumentation, software and reagents for real-time analysis of living cell interactions via Atto Bioscience for $25 mil. in cash. Privately held Atto is expected to generate sales of $6 mil. in 2004. The business complements BD's flow cytometry offerings and expands the firm's life science, drug and biotech presence...